Literature DB >> 15544697

Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study.

A Mocroft1, A d'Arminio Monforte, O Kirk, M A Johnson, N Friis-Moller, D Banhegyi, A Blaxhult, F Mulcahy, J M Gatell, J D Lundgren.   

Abstract

OBJECTIVES: To describe changes in the proportions of patients admitted to hospital and the duration of admission during the month of March between 1995 and 2003 and to describe the factors related to admission for 9802 patients from EuroSIDA, a pan-European, observational cohort study.
METHODS: Generalized estimating equations were used to determine changes over time in the proportion of patients admitted and the median duration of admission. Logistic regression was used to determine factors related to admission in March 1995, March 1998 and March 2001.
RESULTS: The proportion of patients admitted during March declined from 7.4% in 1995 to 2.6% in 2003. After adjustment, the estimated reduction in the proportion of patients admitted was 5.5% per year [95% confidence interval (CI) 2.5-8.5%; P=0.0004], a 26% reduction. The median duration of hospital admission declined by 58% from 12 days in 1995 [interquartile range (IQR) 5-19 days] to 5 days in 2003 (IQR 3-12 days), a significant decline of 0.7 days per year after adjustment (95% CI 0.5-0.9 days; P=0.031). Patients with a lower CD4 lymphocyte count, and with an AIDS diagnosis made within the 3 months prior to March, all had increased odds of admission during March 1995, 1998 or 2001. In March 2001, patients whose treatment regimen was changed as a consequence of toxicities had increased odds of admission [odds ratio (OR) 2.34; 95% CI 1.26-4.37; P=0.0074]. In addition, patients who were hepatitis C virus-positive during March 2001 (OR 1.66; 95% CI 1.02-2.68; P=0.041) had increased odds of admission.
CONCLUSIONS: There has been a considerable decline in both the proportion of patients admitted to hospital and the median duration of the stay. Patients with hepatitis C had increased odds of admission, but there was little evidence of an increase in admissions among patients taking highly active antiretroviral therapy (HAART) associated with serious adverse events, although longer follow up is required.

Entities:  

Mesh:

Year:  2004        PMID: 15544697     DOI: 10.1111/j.1468-1293.2004.00250.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  21 in total

Review 1.  The impact of disease stage on direct medical costs of HIV management: a review of the international literature.

Authors:  Adrian Levy; Karissa Johnston; Lieven Annemans; Andrea Tramarin; Julio Montaner
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Analysis of HIV/AIDS DRG in Portugal: a hierarchical finite mixture model.

Authors:  Sara Simões Dias; Valeska Andreozzi; Rosário O Martins
Journal:  Eur J Health Econ       Date:  2012-08-05

3.  Trends and causes of hospitalizations among HIV-infected persons during the late HAART era: what is the impact of CD4 counts and HAART use?

Authors:  Nancy F Crum-Cianflone; Greg Grandits; Sara Echols; Anuradha Ganesan; Michael Landrum; Amy Weintrob; Robert Barthel; Brian Agan
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

4.  Contemporary costs of HIV healthcare in the HAART era.

Authors:  Kelly A Gebo; John A Fleishman; Richard Conviser; James Hellinger; Fred J Hellinger; Joshua S Josephs; Philip Keiser; Paul Gaist; Richard D Moore
Journal:  AIDS       Date:  2010-11-13       Impact factor: 4.177

5.  Hospitalizations in a cohort of HIV patients in Australia, 1999-2007.

Authors:  Kathleen Falster; Handan Wand; Basil Donovan; Jonathan Anderson; David Nolan; Kerrie Watson; Jo Watson; Matthew G Law
Journal:  AIDS       Date:  2010-06-01       Impact factor: 4.177

6.  Hospitalization rates of people living with HIV in the United States, 2009.

Authors:  Marcus A Bachhuber; William N Southern
Journal:  Public Health Rep       Date:  2014 Mar-Apr       Impact factor: 2.792

7.  Hospitalization risk following initiation of highly active antiretroviral therapy.

Authors:  S A Berry; Y C Manabe; R D Moore; K A Gebo
Journal:  HIV Med       Date:  2009-12-08       Impact factor: 3.180

8.  HIV patients with psychiatric disorders are less likely to discontinue HAART.

Authors:  Seth Himelhoch; Clayton H Brown; James Walkup; Geetanjali Chander; P Todd Korthius; Joseph Afful; Kelly A Gebo
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

9.  Access to HAART and utilization of inpatient medical hospital services among HIV-infected patients with co-occurring serious mental illness and injection drug use.

Authors:  Seth Himelhoch; Geetanjali Chander; John A Fleishman; James Hellinger; Paul Gaist; Kelly A Gebo
Journal:  Gen Hosp Psychiatry       Date:  2007 Nov-Dec       Impact factor: 3.238

10.  Antibiotics-related adverse events in the infectious diseases department of a French teaching hospital: a prospective study.

Authors:  J Courjon; C Pulcini; E Cua; K Risso; F Guillouet; E Bernard; P-M Roger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-07-23       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.